TABLE 8-5Vaccines Against Biologic Threat Agents

Agent or DiseaseStage of DevelopmentTypeCivilian Utility
Anthraxlicensedinactivated toxinsyes
Plaguelicensedinactivated bacteriano
TularemiaINDlive attenuatedno
EEEINDinactivated virusno
WEEINDinactivated virusno
VEEINDlive attenuatedno
VEEINDinactivated virusno
BotulismINDtoxoidsyes
Q FeverINDinactive antigenno
Smallpoxlicensedavirulent vaccinia virusyes
SmallpoxINDavirulent vaccinia virusyes
Ebola/Marburgpreclinicalviral replicon/DNAno
SEBpreclinicaltoxoidno
Ricinpreclinicaltoxoidno
Brucellosispreclinical
no
Yellow Feverlicensedlive attenuated virusno
Rift Valley feverINDinactivated virusno
Rift Valley feverINDlive attenuated virusno
Junin virusINDlive attenuated virusno
Hantaan virusINDengineered vacciniano
DengueINDlive attenuated virusno

From: 8, Availability, Safety, and Efficacy of Drugs and Other Therapies

Cover of Chemical and Biological Terrorism
Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response.
Institute of Medicine (US) Committee on R&D Needs for Improving Civilian Medical Response to Chemical and Biological Terrorism Incidents.
Washington (DC): National Academies Press (US); 1999.
Copyright 1999 by the National Academy of Sciences. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.